Literature DB >> 12788337

Schizophrenia: from phenomenology to neurobiology.

Albert Hung Choy Wong1, Hubert H M Van Tol.   

Abstract

Schizophrenia is a common and debilitating illness, characterized by chronic psychotic symptoms and psychosocial impairment that exact considerable human and economic costs. The literature in electronic databases as well as citations and major articles are reviewed with respect to the phenomenology, pathology, treatment, genetics and neurobiology of schizophrenia. Although studied extensively from a clinical, psychological, biological and genetic perspective, our expanding knowledge of schizophrenia provides only an incomplete understanding of this complex disorder. Recent advances in neuroscience have allowed the confirmation or refutation of earlier findings in schizophrenia, and permit useful comparisons between the different levels of organization from which the illness has been studied. Schizophrenia is defined as a clinical syndrome that may include a collection of diseases that share a common presentation. Genetic factors are the most important in the etiology of the disease, with unknown environmental factors potentially modulating the expression of symptoms. Schizophrenia is a complex genetic disorder in which many genes may be implicated, with the possibility of gene-gene interactions and a diversity of genetic causes in different families or populations. A neurodevelopmental rather than degenerative process has received more empirical support as a general explanation of the pathophysiology, although simple dichotomies are not particularly helpful in such a complicated disease. Structural brain changes are present in vivo and post-mortem, with both histopathological and imaging studies in overall agreement that the temporal and frontal lobes of the cerebral cortex are the most affected. Functional imaging, neuropsychological testing and clinical observation are also generally consistent in demonstrating deficits in cognitive ability that correlate with abnormalities in the areas of the brain with structural abnormalities. The dopamine and other neurotransmitter systems are certainly involved in the treatment or modulation of psychotic symptoms. These broad findings represent the distillation of a large body of disparate data, but firm and specific findings are sparse, and much about schizophrenia remains unknown.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788337     DOI: 10.1016/s0149-7634(03)00035-6

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  53 in total

1.  Discovery of potential antipsychotic agents possessing pro-cognitive properties.

Authors:  Jelveh Lameh; Krista McFarland; Jorgen Ohlsson; Fredrik Ek; Fabrice Piu; Ethan S Burstein; Ali Tabatabaei; Roger Olsson; Stefania Risso Bradley; Douglas W Bonhaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-15       Impact factor: 3.000

Review 2.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

3.  Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes.

Authors:  Emilie Lauressergues; Bart Staels; Karine Valeille; Zouher Majd; Dean W Hum; Patrick Duriez; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-24       Impact factor: 3.000

4.  Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain.

Authors:  Dhruba J Bharali; Ilona Klejbor; Ewa K Stachowiak; Purnendu Dutta; Indrajit Roy; Navjot Kaur; Earl J Bergey; Paras N Prasad; Michal K Stachowiak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-28       Impact factor: 11.205

5.  Modelling schizophrenia using human induced pluripotent stem cells.

Authors:  Kristen J Brennand; Anthony Simone; Jessica Jou; Chelsea Gelboin-Burkhart; Ngoc Tran; Sarah Sangar; Yan Li; Yangling Mu; Gong Chen; Diana Yu; Shane McCarthy; Jonathan Sebat; Fred H Gage
Journal:  Nature       Date:  2011-04-13       Impact factor: 49.962

Review 6.  Nonviral gene transfection nanoparticles: function and applications in the brain.

Authors:  Indrajit Roy; Michal K Stachowiak; Earl J Bergey
Journal:  Nanomedicine       Date:  2008-03-03       Impact factor: 5.307

Review 7.  Use of transcranial magnetic stimulation to influence behavior.

Authors:  Benzi M Kluger; William J Triggs
Journal:  Curr Neurol Neurosci Rep       Date:  2007-11       Impact factor: 5.081

8.  The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.

Authors:  D M Weiner; H Y Meltzer; I Veinbergs; E M Donohue; T A Spalding; T T Smith; N Mohell; S C Harvey; J Lameh; N Nash; K E Vanover; R Olsson; K Jayathilake; M Lee; A I Levey; U Hacksell; E S Burstein; R E Davis; M R Brann
Journal:  Psychopharmacology (Berl)       Date:  2004-07-16       Impact factor: 4.530

9.  Altered fatty acid concentrations in prefrontal cortex of schizophrenic patients.

Authors:  Ameer Y Taha; Yewon Cheon; Kaizong Ma; Stanley I Rapoport; Jagadeesh S Rao
Journal:  J Psychiatr Res       Date:  2013-02-18       Impact factor: 4.791

Review 10.  Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.

Authors:  Mohammad M Khan
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.